NMDAR2B tyrosine phosphorylation regulates anxiety-like behavior and CRF expression in the amygdala

Molecular Brain

Volumn 3, Issue 1, 2010, Pages

  Delawary, Mina ^a   Tezuka, Tohru ^a   Kiyama, Yuji ^a   Yokoyama, Kazumasa ^a   Inoue, Takeshi ^a   Hattori, Satoko ^b,c   Hashimoto, Ryota ^d,e,f   Umemori, Hisashi ^g   Manabe, Toshiya ^a,c   Yamamoto, Tadashi ^a   Nakazawa, Takanobu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PHENYLALANINE; TYROSINE DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; BRAIN REGION; CENTRAL NUCLEUS (AMYGDALA); CEREBELLUM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HIPPOCAMPUS; HOMOZYGOSITY; HORMONE BLOOD LEVEL; HYPOTHALAMUS; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; AMYGDALOID NUCLEUS; ANIMAL; ANIMAL BEHAVIOR; ANXIETY; C57BL MOUSE; GENE TARGETING; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TRANSGENIC MOUSE;

MUS;

AMYGDALA; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CORTICOTROPIN-RELEASING HORMONE; GENE KNOCK-IN TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHORYLATION; RECEPTORS, N-METHYL-D-ASPARTATE; TYROSINE;

EID: 78649475878     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-3-37     Document Type: Article

References (31)

1. Overview of key data from the European study of the epidemiology of mental disorders (ESEMeD). J Alonso JP Lepine, J Clin Psychiatry 2007 68 3 9 10.4088/JCP.0207e03 17288501
2. Neurobiologic basis of anxiety and its treatment. C Salzman EK Miyawaki P le Bars TN Kerrihand, Harv Rev Psychiatry 1993 1 197 206 10.3109/ 10673229309017080 9384849
3. The role of glutamate in anxiety and related disorders. BM Cortese KL Phan, CNS Spectr 2005 10 820 830 16400245
4. Effects of selective NMDA and non-NMDA blockade in the nucleus accumbens on the plus-maze test. G Martinez C Ropero A Funes E Flores C Blotta AI Landa PA Gargiulo, Physiol Behav 2002 76 219 224 10.1016/S0031-9384(02)00704-7 12044594
5. Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice. JL Wiley AF Cristello RL Balster, Eur J Pharmacol 1995 294 101 107 10.1016/0014-2999(95)00506-4 8788421
6. NMDA receptor subunits: diversity, development and disease. S Cull-Candy S Brickley M Farrant, Curr Opin Neurobiol 2001 11 327 335 10.1016/S0959-4388(00) 00215-4 11399431
7. Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. DW Choi, Trends Neurosci 1988 11 465 469 10.1016/0166-2236(88)90200-7 2469166
8. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. JW McDonald MV Johnston, Brain Res Rev 1990 15 41 70 10.1016/0165-0173(90)90011-C 2163714
9. Memories of NMDA receptors and LTP. GL Collingridge TVP Bliss, Trends Neurosci 1995 18 54 56 10.1016/0166-2236(95)93868-X 7537406
10. Src kinases: a hub for NMDA receptor regulation. MW Salter LV Kalia, Nat Rev Neurosci 2004 5 317 328 10.1038/nrn1368 15034556
11. Regulation of NMDA receptors by phosphorylation. BS Chen KW Roche, Neuropharmacol 2007 53 362 368 10.1016/j.neuropharm.2007.05.018 (Pubitemid 47212246)
12. Involvement of NMDAR2A tyrosine phosphorylation in depression-related behavior. S Taniguchi T Nakazawa A Tanimura Y Kiyama T Tezuka AM Watabe N Katayama K Yokoyama T Inoue H Izumi-Nakaseko S Kakuta K Sudo Y Iwakura H Umemori T Inoue NP Murphy K Hashimoto M Kano T Manabe T Yamomoto, EMBO J 2009 28 3717 3729 10.1038/emboj.2009.300 19834457
13. NR2B tyrosine phosphorylation modulates fear learning as well as amygdaloid synaptic plasticity. T Nakazawa S Komai AM Watabe Y Kiyama M Fukaya F Arima-Yoshida R Horai K Sudo K Ebine M Delawary J Goto H Umemori T Tezuka Y Iwakura M Watanabe T Yamamoto T Manabe, EMBO J 2006 25 2867 2877 10.1038/sj.emboj.7601156 16710293
14. Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety. ME Keck, Amino Acids 2006 31 241 250 10.1007/s00726-006-0333-y 16733617
15. A role for corticotrophin releasing factor and urocortin in behavioral responses to stressors. GF Koob SC Heinrichs, Brain Res 1999 848 141 152 10.1016/S0006-8993(99)01991-5 10612706
16. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. JM Reul F Holsboer, Curr Opin Pharmacol 2002 2 23 33 10.1016/S1471-4892(01)00117-5 11786305
17. CRF and CRF receptors: role in stress responsivity and other behaviors. TL Bale WW Vale, Annu Rev Pharmacol Toxicol 2004 44 525 557 10.1146/annurev. pharmtox.44.101802.121410 14744257
18. Overproduction of corticotrophin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. MP Strenzel-Poore SC Heinrichs S Rivest GF Koob WW Vale, J Neurosci 1994 14 2579 2584 8182429
19. Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. SC Heinrichs EM Pich KA Miczek KT Britton GF Koob, Brain Res 1992 581 190 197 10.1016/0006-8993(92) 90708-H 1327398
20. Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. G Liebsch R Landgraf R Gerstberger JC Probst CT Wotjak M Engelmann F Holsboer A Montkowski, Regul Pept 1995 59 229 239 10.1016/0167-0115(95)00099-W 8584759
21. A robust animal model of state anxiety: fear-potentiated behavior in the elevated plus-maze. SM Korte SF De Boer, Eur J Pharmacol 2003 463 163 175 10.1016/S0014-2999(03)01279-2 12600708
22. Targeted gene mutation approaches to the study of anxiety-like behavior in mice. A Holmes, Neurosci Biobehav Rev 2001 25 261 273 10.1016/S0149-7634(01) 00012-4 11378180
23. Recent advances in the neurobiology of anxiety disorders. SJ Mathew RB Price DS Charney, Am J Med Genet Part C Semin Med Genet 2008 148C 89 98 10.1002/ajmg.c.30172 18412102
24. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. JM Boyce-Rustay A Holmes, Neuropsychopharmacol 2006 31 2405 2414 10.1038/sj.npp.1301039 (Pubitemid 44607058)
25. Unilateral block of NMDA receptors in the amygdala prevents predator stress-induced lasting increases in anxiety-like behavior and unconditioned startle-effective hemisphere depends on the behavior. RE Adamec P Burton T Shallow J Budgell, Physiol Behav 1999 65 739 751 10.1016/S0031-9384(98)00225-X 10073475
26. N-methyl-D-aspartate (NMDA)-mediated corticotropin-releasing factor (CRF) release in cultured rat amygdala neurons. MS Cratty DL Birkle, Peptides 1999 20 93 100 10.1016/S0196-9781(98)00147-8 10098629
27. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. A Holmes M Heilig NM Rupniak T Steckler G Griebel, Trends Pharmacol Sci 2003 24 580 588 10.1016/j.tips.2003.09.011 14607081
28. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. KE Habib KP Weld KC Rice J Pushkas M Champoux S Listwak EL Webster AJ Atkinson J Schulkin C Contoreggi GP Chrousos SM McCann SJ Suomi JD Higley PW Gold, Proc Natl Acad Sci USA 2000 97 6079 6084 10.1073/pnas.97.11.6079 10823952
29. Orphanin FQ/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis. NP Murphy NT Maidment, J Neurochem 1999 73 179 186 10.1046/j.1471-4159.1999.0730179.x 10386969
30. The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist. TZ Baram DT Chalmers C Chen Y Koutsoukos EB De Souza, Brain Res 1997 770 89 95 10.1016/S0006-8993(97) 00759-2 9372207
31. Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR2 (NR2B) subunit of the N-methyl-D-aspartate receptor. T Nakazawa S Komai T Tezuka C Hisatsune H Umemori K Semba M Mishina T Manabe T Yamamoto, J Biol Chem 2001 276 693 699 10.1074/jbc.M008085200 11024032